A Window to the Israeli Pharma and Biotech Industries Workshop Agenda January 13-17,2019

סדנת "חשיפה לתעשיית הפארמה והביוטק בישראל" מאורגנת זו השנה השנייה על ידי ScienceAbroad בחסות חברת טבע ובשיתוף פעולה עם המרכז לקליטה במדע והאגף ליזמות עסקית במשרד העליה והקליטה.

הסדנא כוללת שלושה ימי עיון בהם הרצאות בכירים, פאנלים של מדענים חוזרים, משאבי אנוש, מגייסים וממשל, יום סיור בתעשייה (טבע, VBL), יום יזמות וחדשנות בחממת סנארה ואירוע נטוורקינג בחסות משותפת של קרן aMoon ורשת 8400 בהשתתפות בכירים מהמשק הישראלי ומשקיעים.

מטרות כלליות 1. לעודד חזרתם של מדענים ישראלים השוהים בחו"ל לתפקידים שונים בתעשייה ולהזדמנויות בתחום היזמות בישראל. 2. להציג את התעשייה הישראלית ואת ההזדמנויות הקיימות עבור מדענים

יעדים 1. להציג למדענים את המגמות בתחומי מחקר ופתוח בתעשייה בישראל 2. לחשוף בפני המדענים הזדמנויות מקצועיות ותעסוקתיות בתעשייה הישראלית ולייצר להם קשרים עם מעסיקים פוטנציאליים 3. לספק כלים למעבר ממחקר אקדמי למחקר יישומי בתעשייה 4. להכיר את תחום היזמות ואת כלי הסיוע והתמריצים שמספקת מדינת ישראל

על ScienceAbroad ארגון המדענים הישראלים בחו"ל ScienceAbroad הוא ארגון ללא כוונות רווח הפועל מאז 2006, לשמירת קשר עם חוקרים ישראלים בעולם והשבת המוחות לישראל. ScienceAbroad הוא קהילה בינלאומית עבור יותר מ- 2800 חוקרים ישראלים ב300 קמפוסים ברחבי העולם. הארגון מפעיל 23 מרכזים בארה"ב, קנדה ואנגליה המנוהלים על ידי מדענים מתנדבים. הארגון מעניק כלים, מפתח קשרים ופותח דלתות למדענים ישראלים המבקשים לשוב לישראל על מנת שיביאו עימם את הידע, הכישרון, הניסיון והקשרים שצברו לאקדמיה ולתעשייה כמנוע צמיחה לישראל.

משתתפים ושותפים יקרים,

אנו מבקשים לברך אתכם על ההחלטה לקחת חלק בסדנת "חשיפה לתעשיית הפארמה והביוטק בישראל" המאורגנת זו השנה השנייה על ידי ScienceAbroad בחסות חברת טבע ובשיתוף פעולה עם המרכז לקליטה במדע והאגף ליזמות עסקית במשרד העליה והקליטה.

הבחירה שלכם היא לרב צעד אמיץ לקראת שינוי נתיב קריירה וחשיפה להזדמנויות חדשות ופחות מוכרות.

סיינס אברוד פועל מזה 12 שנה לשמירת קשר עם ישראלים בעלי תארים מתקדמים ברחבי העולם והשבת המוחות לישראל.

חזוננו הוא שישראל תהא אבן שואבת לחוקרים מכל העולם ואנו מאמינים כי מינוף ומיצוב המו"פ בתעשייה בישראל לצד ניתוב מדענים למסלולי תעשייה ויזמות יכולים להביא להגשמת החזון.

מנתונים מעודכנים לשנת 2017 עולה כי 11% מכלל המסיימים לימודי דוקטורט במוסדות להשכלה גבוהה בישראל, מתגוררים בחו"ל במשך למעלה משלוש שנים!

עזיבת מדענים את ישראל גוררת השלכות למשק הישראלי בדמות הפסד הכנסות עתידיות מן התושבים שעזבו.

בסקרים שקיימנו בשנה האחרונה מצאנו כי החסם העיקרי לחזרה לישראל הוא התעסוקה. מחד מיעוט של משרות באקדמיה ומאידך קושי להשתלב במו"פ בתעשייה בישראל בגלל חוסר ניסיון תעסוקתי בתעשייה והיצע משרות נמוך.

רק 7% מבוגרי דוקטורט במדעי החיים מצליחים למצוא עבודה באקדמיה, אף שזו לרוב כוונתם. עוד 9% משתלבים בתעשיית הביוטק, כולל האגרו-טק (חדשנות בחקלאות). במערכת הבריאות (לרוב כעובדי ומנהלי מעבדות) משתלבים עוד כ14.5%-. כלומר, רק כ30%- עובדים ממש במקצוע. ( ד"ר נורית איל, מתוך מחקר של התוכנית להשבת אקדמאים)

כדי להקים בישראל תעשיית מדעי חיים משגשגת שתהא אבן שואבת לאנשי מחקר ופיתוח נדרשים הון אנושי והון.

וכאן אנחנו פוגשים אתכם – אתם ההון האנושי, אתם מנוע הצמיחה של ישראל!

אנו מקווים שהתכנית תאפשר לכם הרחבה של הידע וההיכרות עם תעשיית מדעי החיים בישראל ובעיקר תאפשר לכם יצירת קשרים שיסייעו לכם בהשתלבות תעסוקתית בישראל.

מאחלים לכם סדנא מוצלחת, נשמח לראות אתכם משתלבים בעוד תכניות של הארגון.

מוניקה לב כהן, ד"ר שמוליק הס, יו"ר מנכ"לית ScienceAbroad מייסד ושותף ScienceAbroad מדענים ישראלים יקרים,

ברוכים הבאים הביתה לישראל.

אנו נרגשים לתת חסות לסדנת ה"חשיפה לתעשיית הפארמה והביוטק בישראל."

לאורך 117 שנות קיומה צמחה חברת טבע לצידה של תעשייה מדעית ישראלית חזקה ומתקדמת. מאז ועד היום, ההון האנושי הישראלי מהווה את אחד המפתחות המשמעותיים ביותר להצלחתה וצמיחתה של תעשיית ביו-פארמה תחרותית וברת-קיימא בישראל .

אנו רואים חשיבות עצומה בהשבת "מוחות ישראלים", כמוך.

הכישרון, הניסיון אותו אתם מביאים והחשיפה למעבדות המחקר המובילות בעולם, יאפשרו לתעשיית הביו-פארמה הישראלית להמשיך להתפתח ולעמוד בחזית המדע. לחברת טבע יש שני מרכזי מו"פ מהגדולים בארץ, בנתניה ובכפר-סבא, המתמחים בפיתוח תרופות אינובטיביות וגנריות – כימיות וביולוגיות כאחד ונשמח לראותך משתלבים בעתיד.

אנו רוצים להודות לארגון "סיינסאברוד" על היוזמה והשותפות בקיום הסדנה השבוע.

בהצלחה לכולנו,

איריס בק קודנר סמנכ"לית בכירה, חברת הנהלת טבע A Window to the Israeli Pharma and Biotech Industries Workshop Agenda

January 13-17,2019

Day 1 – Introduction and Preclinical Development (Tel Aviv)

Opening Remarks Dr. Shmuel Hess – Chairman, ScienceAbroad Ms. Iris Beck-Codner - Executive Vice President, Global Brand & Communications , 09:00-09:45 Ms. Granit Ben Ezra Zinger - Director of the Center for Absorption in Science, MoAI Ms. Irus Huminer, - Director of the Department of Business Entrepreneurship, MoAI Mr. Yossi Weinstock - Partner at Pearl Cohen Zedek Latzer Baratz

Introduction to Drug Development 09:45-10:30 Dr. Elijahu Berkovich - Clexio Biosciences

10:30-10:45 Break

Drug Discovery in Industry Setting 10:45-11:30 Dr. Yael Marantz - VP Nonclinical Development, Head of ABIC site in IL, Teva Pharmaceuticals

Introduction to Biosimilar Drugs Development 11:30-12:15 Dr. Nir Shapir - VP Biologics, CMC Biosimilars, Teva Pharmaceuticals

12:15-13:00 Lunch

Clinical Pharmacology 13:00-13:45 Dr. Ofer Spiegelstein - VP, Innovation Initiatives, Specialty R&D, Teva Pharmaceuticals

Introduction to CMC 13:45-14:30 Dr. Daniella Gutman - VP, Generic R&D, and site head & Hungary, Teva Pharmaceuticals

14:30-14:45 Break

Preclinical Pharmacology 14:45-15:30 Dr. Aric Orbach – DVM, Senior Director, Head of Pharmacology, Teva Pharmaceuticals

Toxicology and ADME 15:30-16:15 Dr. Hilla Kedar - Senior Director, Head of Nonclinical Safety, Teva Pharmaceuticals Day 2 – Clinical Development (Tel Aviv)

Introducing Teva 09:00-09:45 Mr. Mati Gill - Head of Government Affairs, Corporate & International Markets, Teva Pharmaceuticals Ms. Eti Raihenshtein – Director, Talent Acquisition International Market, Teva Pharmaceuticals

Planning of a Clinical Trial 09:45-10:30 Dr. Eran Harary, - Senior Director, Global Clinical Development, Neuropsychiatry, Teva Pharmaceuticals

10:30-10:45 Coffee Break

Operational Aspects of Clinical Trials 10:45-11:30 Ms. Shoshi Friedman, B.S.N R.N - VP Global Clinical Operations, Teva Pharmaceuticals

Drug Manufacturing to Support a Clinical Study 11:30-12:15 Dr. Tal Hasson - Associate Director, Analytical Development, Specialty CMC, Teva Pharmaceuticals

12:15-13:00 Lunch

Regulatory Affairs 13:00-13:45 Ms. Levana Volovsky - Director, Global Regulatory Affairs, CNS, Teva Pharmaceuticals

Legal Aspects in Drug Development and Tech Transfer 13:45-14:30 Ms. Efrat Shalom-Berensohn, LL.M - Senior Director, General Counsel, Global R&D, Teva Pharmaceuticals

14:30-14:45 Break

Returning Scientists Panel Moderator: Dr. Ianai Fishbein – Associate Director, Nonclinical Development, Teva Pharmaceuticals Dr. Moshe Ben-David – R&D Director, Ukko 15:30-16:30 Dr. Reut Shema – Associate, aMoon Fund Dr. Arik Zur - Associate Director of Clinical Pharmacology, BioLineRx Dr. Moran Grossman – Senior Scientist at MabTrix Dr. Irit Carmi-Levy - Project Director at BioLineRx Day 3 – Cross Functional Work (Tel Aviv)

09:00-09:45 – Therapy of the Future: Opportunities and Challenges Mr. Nadav Eshkol - Technology and Process Development Manager,

Translational Medicine, 09:45-10:30 Dr. Jennifer Dreymann - Director, Translational Medicine Expert, Teva Pharmaceuticals

10:30-10:45 Coffee Break

Pharmacovigilance 10:45-11:30 Ms. Orit Stern-Maman - VP Global Patient Safety & Pharmacovigilance, Teva Pharmaceuticals

Business Development 11:30-12:15 Mr. Itamar Yaron - Senior Director, M&A and Global Alliances, Business Development & Strategy, Teva Pharmaceuticals

12:15-13:00 Lunch

Commercialization 13:00-13:45 Mr. Avinoam Sapir – SVP, Cluster Manager – Teva Israel, Turkey, Ukraine & Africa, Teva Pharmaceuticals

Personalized Medicine and Digital Health 13:45-14:30 Dr. Daphna Laifenfeld - Chief Strategy Officer at Ibex Medical Analytics

14:30-14:45 Break

The Israeli Life Science Industry – Trends and Opportunities 14:45-15:30 Dr. Itai Kela - Senior Director - Head of Healthcare and Biotechnology sectors at Israel Innovation Authority

HR Panel Moderator: Ms. Lizi Shoov London – Partner & Managing Director, Nisha Group Ms. Liat Duani - Senior Consultant, Diva Keren Creative HR 15:30-17:00 Ms. Cohav Nir - Senior Manager, Sourcing & Employer Branding, Teva Pharmaceuticals Ms. Limor Lior - Organization Development Manager & HRP, Pluristem Therapeutics Mr. Jonathan Solomon - CEO at BiomX Ltd. Day 4 – Innovation and Startups (Ra’anana)

Introduction to the Innovation and Startup World 09:00-10:15 Mr. Assaf Barnea – CEO Sanara Ventures

Governmental and NGO’s Assistance Session Ministry of Aliya and Integration – Business Entrepreneurship Dept Ms. Irus Huminer – Director of the Department of Business Entrepreneuship, MoAI 10:15-11:30 IATI Ms. Karin Mayer Rubinstein - CEO and President, IATI The Health Network-8400 Ms. Daphna Murvitz – Co-founder and CEO, 8400

11:30-11:45 Coffee Break

Failure and Success Factors of Technological Startup Companies – 11:45-12:30 Lessons from Personal Experience Mr. Zohar Gendler - CEO & Managing Partner, NGT3

Introduction to Digital Health 12:30-13:15 Mr. Ophir Shahaf - VP Business Development at eHealth Ventures Incubator

13:15-13:55 Lunch

Venture Capital Funds Panel Moderator: Dr. Neta Kela-Madar – Head of Innovation and Entrepreneurship Center, SCE Dr. Yuval Cabilly – Founder and Managing Partner, Israel Biotech Fund 13:55-15:30 Dr. Pini Orbach - Head of Pharma at Arkin Holdings Dr. Dov Tamarkin - CEO at Tamarkin Ventures Dr. Omri Amirav-Drory - Founding Partner at tech.bio

15:30-15:45 Break

Startup Panel Moderator: Dr. Shmuel Hess - CEO, Enlivex Therapeutics Dr. Amir Bahar - Co-Founder COO & Clinical Dir. Nurami Medical 15:45-17:30 Mr. Yoav Grinstein – COO, Our Clinical Trial Dr. Eyal Fima – Entrepreneur, Advisor Dr. Roni Mamluk – CEO, Ayala Pharmaceuticals

Networking Event – co-hosted by aMoon and 8400 18:00 aMoon offices, Ra’anana Day 5 – Tours

10:00-13:00 Tour at Teva Pharmaceuticals, Kfar Saba

14:00-17:00 Tour at VBL Therapeutics, Modi’in

*Schedule may be subject to change.

Important Note Attendance at this event is mandatory, in particular for the attendees who have received funding for their travel.

ימים 1-3 (13-15 בינואר):

מיקום הסדנה: משרד עו"ד Pearl Cohen Zedek Latzer Baratz , דרך מנחם בגין 121, מגדל שרונה, תל אביב, קומה 53. כניסה רגלית לבניין דרך מנחם בגין ולא דרך שרונה. הגעה ברכב: חנייה בתשלום בבניין עזריאלי שרונה, כניסה לחניה דרך מנהרת לובה אליאב (לרשום בווייז "חניון עזריאלי שרונה") או בחניונים בסביבה. כמו כן, ניתן להחנות את הרכב בנתיב המהיר ולנסוע עם השאטל ללא תשלום.

חניה בתשלום: בבניין עזריאלי שרונה, כניסה לחניה דרך מנהרת לובה אליאב (לרשום בווייז "חניון עזריאלי שרונה") או בחניונים בסביבה.

תחבורה ציבורית: ניתן להגיע ברכבת (תחנת השלום) או אוטובוס.

יום 4 (16 בינואר):

מיקום הסדנה: חממת סנארה, רח' זרחין 13, בניין C, רעננה. חניה בתשלום: יש חניון בתשלום צמוד לבניין.

אירוע נטוורקינג: במשרדי קרן aMoon רח' ירושלים 34, בית גמלא, כניסה ,B קומה 6, רעננה. חניה: ישנה חניה סמוכה לבניין, קחו כרטיס חניה ונדביק עליו מדבקה המאפשרת יציאה חינם מהחניון.

יום 5 (17 בינואר):

סיור בטבע: רח' אלי הורוביץ 18, כפר סבא סיור בVBL Therapeutics-: הסתת 8, מודיעין הגעה: הסעה מאורגנת מכפר סבא למודיעין ובחזרה

Contact Information:

Liron Even-Faitelson Tal Yoetz Monika Lev Cohen Anat Weiss [email protected] [email protected] [email protected] [email protected] 053-2800793 054-8886347 052-3847949 050-5617246 A Window to Industry Workshop Participants - 2019

[email protected] ד"ר אנה מלישקביץ Anna Zemel-Malishkevich, PhD

I have recently completed my postdoctoral studies in the Cancer Immunology Center, in the laboratory of immunologist Prof. Shawn Demehri at Massachusetts General Hospital, Harvard Medical School, Boston. During my postdoc, I gained valuable knowledge in cancer immunology and future therapeutic potential for cancer. The focus of my project was to determine the role of the immune system in the regulation of the early stages of breast cancer development. Prior to that, I was a graduate student in the lab of Prof. Illana Gozes at Tel Aviv University. During my PhD, I established new biomarkers in lymphocytes of Alzheimer's disease patients for a better diagnosis and prognosis of the disease. My M.Sc. in Immunology allowed me exposure to industry - as an Immunologist I spent one year at “Omrix” Biotech Company. During all my years of work and research, I have utilized multiple techniques. I am particularly passionate about hypothesis-driven strategies, to interrogate cancer biology, identify and validate new drug targets, discover and develop chemical tools (molecular docking of the small molecules) and drugs acting on these targets, identify predictive biomarkers, and elucidate mechanisms of drug sensitivity of resistance.

[email protected] ד"ר אריאל פייגלין Ariel Feiglin, PhD

Computational Biologist (Ph.D.) with the Department of Biomedical Informatics (DBMI) at the Harvard Medical School and with the Center for Functional Cancer Epigenetics (CFCE) at the Dana Farber Cancer Institute. My recent research has focused on tissue specific gene expression patterns in rare disease and cancer epigenetics. Currently I am developing a computational and experimental platform that aims to enhance cancer-immunotherapy treatments by inducing potent neoantigens in tumors.

[email protected] ד"ר אסף רז Assaf Raz,PhD

Assaf Raz focuses on the development of antimicrobial biologics against Gram-positive and Gram-negative pathogens. He received his PhD from Rockefeller University and is currently a scientist in the laboratory of Vincent Fischetti at Rockefeller. He has served as a consultant at ContraFect corp. for 8 years, and is a member of the core team responsible for microbiology at DiscitisDX corp. He participated in Entrepreneurship Lab NYC class of 2018, promoting the commercialization of the lysibody technology he co-invented. He participated in Entrepreneurship Lab NYC class of 2018, promoting the commercialization of the lysibody technology he co-invented. This technology is currently funded through Tri-I TDI for preclinical development. He currently develops phage lysin technology for the treatment of multidrug resistant P. aeruginosa and CRE organisms. Assaf is an author of 13 peer reviewed publications, 2 book chapters, and 4 patents. Participants - 2019 [email protected] ד"ר אביטל שריר-עברי Avital Sharir-Ivry, PhD

I am currently a Postdoctoral Researcher at the Bioengineering Department at McGill University, in the Computational & System Biology lab of prof. Yu Xia. Here I study the design principles of proteins by integrating bioinformatics structural biology tools with computational evolution tools. My studies are based on proteome-level analysis of protein structures and mutation patterns, allowing me to have a highly-detailed system-level analysis. I also study the patterns of disease mutations in proteins and how they are affected by the protein 3D structure. I obtained my M.Sc. and Ph.D. in Computational Chemistry from the Pharmacy Dept. at the Hebrew University in the lab of Prof. Avital Shurki. There, I was developing computational methods that combine quantum and classical chemistry tools (QM/MM methods) to study chemical reactions in large systems. I applied the methods to study chemical reactions catalyzed by enzymes and the effect of mutations. My B.Sc. in Chemistry and Physics was obtained from the Hebrew University. [email protected] ד"ר בלה גרויסמן Bella Groisman, PhD

I have earned my PhD from the Cell Research and Immunology Dept., Tel Aviv University. The focus of my research was the characterization of the protein complexes involved in ERAD and the novel role of EDEM1. After graduation I joined the Molecular Genetics Dept. at the Weizmann Institute, before moving on to do a postdoc at the University of Toronto, Igor Stagljar lab. During my postdoctoral studies I have contributed to the development of the Mammalian-Membrane Two Hybrid Technology (MaMTH) – the proteomics approach for mapping membrane protein-protein interactions in-vivo in mammalian cells. The MaMTH assay was patented through UofT and recently the patent has been issued in USA. At my last role at McMaster University I have joined the cancer immunotherapy team, facilitating the preclinical in-vitro characterization of the manufactured TAC-T cells. We were able to cure CD19- tumor bearing mice - the product will be tested in clinical trials early this year [email protected] ד"ר דנה גולדנברג Dana Goldenberg, PhD

I received my PhD from the Faculty of Agriculture, Veterinary and Animals sciences, Dept. of Virology and Immunology at the Hebrew University. My Ph.D. thesis was “Genetic and immunologic characterization of the sigma C protein of Avian Reovirus”. The goal of this study was to characterize and understand the immunologically significant region in sigma C protein, which is crucial for immune protection. This study allowed the Israeli vaccine industry to produce a targeted vaccine, which significantly reduced the occurrence of outbreaks updated to 2018. I was accepted to the BARD program postdoctoral fellowship to conduct immunology research on Newcastle disease vaccines. The objectives of this study are to develop a vaccine platform, by generating a new recombinant virus using reverse-genetics technique. This research is conducted at the USDA, Exotic and Emerging Avian Viral Diseases Research Unit, Athens, GA. [email protected] ד"ר דני זאבי Danny Zeevi, PhD

I am currently a visiting scientist at the department of human genetics at UCLA, where I study the genetic basis of complex traits and diseases. I did my Postdoc at Princeton University and UCLA, where I studied the genetic basis of height in extremely large Israeli families. My PhD is from the Departments of Computer Science and Cell Biology at the Weizmann Institute of Science, where I studied gene regulation by building a robotic automated system for genetic engineering of large number of cells in parallel. I completed my MSc in Biology at the department of Physics of Complex Systems at Weizmann, and BSc in Physics and Biology at Tel Aviv University. I enjoy combining bioinformatics and statistical genetics with wet-lab/field work and my passion is studying anything related to genetics. Previous to the academia, I served as a pilot in the Israeli Air Force. Participants - 2019

[email protected] ד"ר דפנה נחמני Daphna Nachmani, PhD

I performed my PhD studies at the Hebrew University in the lab of Prof. Ofer Mandelboim at Hadassah Medical School. My research focused on viral-immunology and immune evasion mechanisms of Herpesviruses with an emphasis on molecular techniques. In my PhD publications I utilized a wide range of immunological and virological methodologies, in addition to primary cell isolation, viral culture and purification, cell imaging, next generation RNA sequencing and more. In 2014 I’ve started my postdoctoral training at Harvard (Boston, USA), where I’m studying the role of RNA modifications in human disease with a focus on hematopoietic biology. Within my postdoc lab, I am leading a small team that is dissecting the molecular mechanisms controlling RNA modifications, translation and protein production in hematopoietic stem cells. In addition to this, together with collaborators around the world, we combine our molecular knowledge with human genetics to identify new disease driver genes mutations. My team and I model these mutations in mice and phenotypically analyze them for disease features. Our ultimate goal is to use our mouse models to develop RNA-based therapies for human hematopoietic stem cell diseases.

[email protected] ד"ר אלעד אליהו Elad Eliahoo, PhD

My background includes both computational biology work and extensive experimental work especially in Virology and Biochemistry of proteins and nucleic acid. My M.Sc. focused on the oncolytic effect of NDV on human cancerous cells. During my doctoral research, I’ve investigated the biochemistry, structural biology and the protein-RNA interactions of the protein Translin. I’ve also identifying proteins that form complexes with Translin and the molecular mechanisms by which these complexes act using quantitative proteomics. As a post-doctoral fellow, I’ve studied the significance of polymorphisms of HCV Serine-protease in mild, severe and cancerous HCV patients and the effect these differences have on the innate immune response and the cell metabolism. Then, I’ve studied the Human Cytomegalovirus protein, TRS1, an innate immune sensor antagonist, and identify the RNAs that associate with it, using next generation RNA sequencing. Currently, my research focuses on developing a viral vaccine to induced non-surgical sterilization/castration of straying cats. Also, I’m the principal lecturer of the Veterinary virology course in Koret School of Veterinary Medicine .

[email protected] ד"ר גולדי א. קוזלוסקי Goldi A. Kozloski, PhD

Education: BS in Biology/Pre-med from Eckerd College, PhD in Biochemistry and Molecular Biology from the University of Miami, Post-doctoral fellowship in Oncology-Hematology from the Sylvester Cancer Center at the University of Miami. In my PhD, I studied receptor signaling and analyzed a unique oncogenic module composed of the membrane mucin, MUC4, and receptor tyrosine kinases, ERBB2/3. This work highlighted MUC4 overexpression as a potent mitogenic signaling amplifier. In my fellowship, I utilized miRNAs to study B-cell signaling aberrations in lymphoma (DLBCL). I elucidated the molecular mechanisms of a master regulator, miR-181a, in NF-kB signaling regulation. miR-181a is now evaluated as a therapeutic tool for NF-kB hyperactivated lymphoma subgroups. Most recently, I held an Assistant Professor position at Barry University Bio-Medical Science Program, and I started a consulting firm that provides a multi-disciplinary research support. I enjoy all aspects of translational research, and I am committed to making a real difference in the lives of people facing challenging medical conditions. Participants - 2019

[email protected] ד"ר יונתן דר Jonatan Darr, PhD

I received my bachelor's degree in biology as a fellow of the Amirim program at the Hebrew University. My Master's and doctoral studies were conducted under the supervision of Dr. Amir Eden and focused on the role of chromatin remodeling complexes in transformation of MRT and AT/RT, two highly aggressive pediatric sarcomas. My work demonstrated a therapeutic potential for Kinase inhibitors and specifically for EGFR inhibitors. During this time, I worked as a teaching assistant in the course “Introduction to Ecology and Population Biology” at the Hebrew University and in the courses “Lab in Biochemistry” and “Lab in Molecular Biology” at the Hadassah College. Following my PhD, I was accepted to the Postdoctoral Fellowship Program at the Helmholtz Center for Environmental Health in Munich, where I joined the lab of Dr. Raffaele Teperino. My research proposal focused on elucidating the role of cell free circulating RNAs in endocrine signaling and metabolic regulation. To achieve this aim I developed a novel method for tissue specific labelling of total RNA that utilizes a novel modified nucleotide and a transgenic model. Currently, I am continuing my research in Munich. [email protected] ד"ר מתי מן Mati Mann, PhD

Mati is currently a postdoctoral scholar in Immunology at the California Institute of Technology in Dr. David Baltimore’s lab. Mati’s main research interest is focused on the effects aging and chronic inflammation have on the hematopoietic system, and specifically, hematopoietic stem cells in both human and mouse models. He received his B.S and MSc in Biochemistry from the Hebrew University, and his PhD in Molecular Genetics and Molecular Cell Biology from the Weizmann Institute of Science studying micro-RNAs and cell fate decisions in the hematopoietic system. Mati also served as a coordinator and lead instructor of basic biology for high school students at the Davidson Institute of Science Education, and is now volunteering in Science Education for high school students around Pasadena

[email protected] ד"ר רון יורטנר (רוני) Dana Goldenberg, PhD

Ron Jortner is a scientist and entrepreneur currently based in Cambridge, UK. He is founder and managing director of Masthead Biosciences, providing life sciences stakeholders with professional assessments and research on assets in the therapeutics, medical devices and diagnostics spaces. Prior to founding Masthead Biosciences, Ron held several research positions in neuroscience and brain imaging, including at the MRC Laboratory for Molecular Biology (LMB) in Cambridge, and at several Max Planck Institutes in Germany. His research focused on visual memory, behavior in virtual environments, and neural processing of odours. Ron did his Ph.D in computational neuroscience at Caltech and the Hebrew University, and completed his B.Sc. in biology (Magna cum laude) at the Hebrew University. He enjoys rock climbing, martial arts, music, and improvisation theater Participants - 2019

[email protected] ד"ר סיגלית מקר Sigalit Meker, PhD

Experienced chemist, passionate about applying chemistry to solve complex biomedical challenges. I received my B.Sc. (2008, magna cum laude) in chemistry from the Hebrew University of Jerusalem, Israel. Later, I continued my studies and graduated as M.Sc. (2011) and Ph.D. (2017, Clore scholar) under the supervision of Prof. Edit Y. Tshuva, focusing on the synthesis of metallo-drugs for cancer therapy, and their mechanistic evaluation. This work was acknowledged by the Israel Chemical Society (ICS), and I was honored with the ICS prize for excellent graduate student. After graduation, I relocated to Singapore and I completed a two-year period as a research fellow at Nanyang Technological University, working with Prof. Nam-Joon Cho. I studied the self-assembly and chemical binding of biomolecules (phospholipids) to oxide surfaces, and their interactions with proteins and cells. My diverse background fits well with my belief that chemistry, being a recurring theme in my work, is a powerful and adaptable tool in biomedical research.

[email protected] ד"ר טל הירש הורן Tal Hirschhorn, PhD

Throughout my undergraduate and graduate studies, I have worked as a researcher in Tel-Aviv University as a joint student in two laboratories specialized in cancer cell and membrane biology. I have enquired extensive academic knowledge in understanding various molecular mechanisms controlling TGF-β superfamily signaling and receptor trafficking in cancer cells, affecting tumor growth and progression. My research has led me to plan, employ and interpret multiple lines of experimentation, including: molecular biology, protein biochemistry, tissue culture, quantitative confocal microscopy and live cell imaging. In addition to my research activities I have been an active instructor, and have received the highest prize awarded to instructors at my level by the Rector of Tel Aviv University. In my current position as a postdoctoral researcher at Columbia University in the city of New York, I study cell death mechanisms and drug discovery for cancer therapeutics. Specifically,I focus on a novel non-apoptotic regulated cell death mechanism recently discovered in our lab, termed ferroptosis.

[email protected] ד"ר טינה נאפסו Tina Napso, PhD

I am a postdoctoral research fellow at the University of Cambridge’s Centre for Trophoblast Research (CTR). I am supported by the EU’s Marie Skłodowska-Curie Fellowship, the Israeli Council for Higher Education Postdoctoral Scholarship Program for Excellence and the British Society for Endocrinology Early Career Grant. My research aims to identify the signals secreted by the placenta, which alter maternal metabolism in favour of fetal nutrient supply. Thus far, I have characterised the first murine placental secretome, by combining unique mouse models with specialised in-vitro techniques. Additionally, I am leading a collaborative study with colleagues at Canadian and Australian universities, in exploring the effect of advanced maternal age on placental function and fetal development. Moreover, I have a comprehensive molecular biology background in human cancer following my PhD at the University of and as a former MIGAL researcher on an Israeli Ministry of Science funded R&D grant. I am also a qualified clinical research associate (CRA) for clinical research studies. Participants - 2019

[email protected] ד"ר תומר נויהאוזר Tomer Noyhouzer, PhD

Tomer Noyhouzer did his Ph.D. in analytical-electrochemistry developing new electrochemical sensing methods at the Hebrew University under the supervision of Prof. Daniel Mandler. He then received the Rotary global grant and went on to work with Prof. Janine Mauzeroll at McGill University on a wide range of projects such as drug delivery, water purification and the design of various electrochemical flow platforms. During his Post-doctorate fellowship, Tomer served as a McGill Senate member and founded ScienceAbroad Montréal. In 2015 Tomer’s involvement in the local entrepreneurship community led him to co-found E-Innovation, a company that was based on two of his patents and served as the VP R&D for 3 years. Currently, Tomer is living in Ottawa where he is working as an expert consultant for emerging startups and mature companies that seek to utilize his in-depth scientific knowledge and business experience.

[email protected] ד"ר יהודה ברודי Yehuda Brody, PhD

My research background as an experimentalist in cellular and molecular biology with expertise in imaging and computational data sciences, allows me to tackle hard problems in biology with novel approaches. This started with my Ph.D (2007-2011 at Bar-Ilan), already, as I worked on the gene expression kinetics and where computer simulation techniques were applied to live cell imaging. My post-doctorate research at the Broad Institute, a Harvard-MIT Partnership, since 2015, deals with the kinetics of somatic mutagenesis as the driving force to the aging process: that study, too, needed a new approach making it possible to stretch the limits of next-generation sequencing, requiring a combination of advanced engineering, wet biology and machine learning applied to image processing. Between 2011 and 2015, at the new faculty of medicine of BIU in , I had the opportunity to design and establish, from scratch, the state-of-the-art scientific center. This involved hiring, training and managing a team of PhDs and postdocs, whose job was to support the researchers and MDs in their research. [email protected] ד"ר רותם גדרון בודובסקי Dr. Rotem Gidron Budovsky

My name is Dr. (M.D.) Rotem Gidron Budovsky, just finishing my PhD at Prof. Yair Reisner lab, immunology department, Weizmann Institute of Science. My PhD topic: "Immune system tolerance to haploidentical donation in bone marrow transplantation and in cellular immunotherapy". I was privileged to be working in a lab that brings science from bench to clinic. Our preclinical protocols are now at their clinical phase in MD Anderson Cancer Center, USA. We have developed special, less aggressive bone marrow transplantation protocols, taken from a genetically un-matched donor. These protocols will enable the possibility of finding a donor to anyone in need of bone marrow donation. The unique outcome of my research will greatly broaden the use of bone marrow transplantation to elderly patients, non-malignant hematological diseases, organ transplantation and cellular immunotherapy, as an "off-the-shelf" product. Another important aspect of my research includes development of protocols for anti-cancer Chimeric Antigen Receptor (CAR) T cell immunotherapy taken from a universal donor. Participants - 2019

[email protected] מעיין קורמן Maayan Korman

I am a PhD candidate in Eyal Gur’s lab at Ben-Gurion University of the Negev. In our lab we study proteolysis in bacteria, which is a process that must be carefully regulated. In some bacterial species, the Pup-proteasome system exists, which is a tagging and degradation system analogous to the eukaryotic ubiquitin-proteasome system. In this system, PafA is the sole ligase that marks proteins for degradation with a protein modifier (Pup). My thesis is focused on understanding PafA regulation. To investigate which regulatory processes govern PafA activity and levels, I used a combination of biochemical, molecular biology, and microbiology methodologies, such as: protein purification, binding and activity assays, cloning, qPCR, western blot analysis, etc. Besides, during my PhD studies, I was a TA of “Biochemistry” and “Interaction between biomolecules” courses. Also, I had the opportunity to be a part of the organizing committee of the 17th FEBS young scientific forum, held in 2017, Jerusalem.

[email protected] מאיה מילר Maya Miller

Maya Miller was born in 1982 in St. Petersburg, Russia. She completed her B.Sc. in chemistry at Technion-Israel Institute of Technology in 2007. She then worked at Teva Pharmaceuticals for 3 years as a project coordinator in the Analytical R&D division. In 2011 she began her graduate studies at the Hebrew University of Jerusalem under the supervision of Professor Edit Y. Tshuva in the field of Bioinorganic Chemistry. Her research is focused on the stereochemical and mechanistic aspects of Ti(IV) phenolato based compounds for cancer treatment.

[email protected] רעיה פייגנבאום-ראם Raya Faigenbaum-Romm

I am a PhD student at the Hebrew University of Jerusalem. My PhD research is interdisciplinary, combining experimental and computational approaches. I use these approaches to study post-transcriptional regulation by small RNAs in bacteria at a system level, under the supervision of Prof. Hanah Margalit. I am in the final year of my PhD studies, expecting to graduate by October 2019. I completed my BSc in Computer Science and Chemistry in Tel-Aviv University. I then continued for MSc studies in Cancer research under the supervision of Prof. Yoel Kloog at Tel-Aviv University. In my PhD I moved to the fields of Microbiology and Computational Biology. I used Escherichia coli as a model organism to study the principles of post-transcriptional regulation by sRNAs. I took part in the development of an experimental-computational methodology for identifying targets that are directly regulated by sRNAs, which generated a lot of novel data and has opened many research directions. Speakers - 2019 A Window to Industry Workshop Speakers - 2019

Amir Bahar, PhD | Nurami Medical COO and co-founder

Dr. Bahar is a multidisciplinary entrepreneur and scientist with over 20 years of experience in preclinical research and over 7 years of experience in managing medical device development. Dr. Bahar received his Ph.D. in Neurobiology from the Weizmann Institute and completed a postdoctoral training at the Mt. Sinai Medical School in New York. After returning to Israel he served as a project manager of an innovative hemostatic device and led its preclinical phase. In 2014 he co-founded Nurami Medical, which develops smart nanofibers scaffolds for neurosurgery. Amir served as Nurami’s CEO between 2014-2018 and now serves as the company’s COO. He managed the company from early idea to the execution of clinical trials and helped raised over $4MM.

Aric Orbach, DVM | Senior Director, Head of Pharmacology, Teva Pharmaceuticals

Aric got his bachelor's degree in Biology at the Givat Ram campus of the Hebrew University. He then went on to study veterinary medicine at the Koret School of Veterinary Medicine (Hebrew University). Recently he received an M.B.A from the Peres Academic Center in Rehovot. As a vet, Aric worked on several veterinary projects and served as a practitioner in a small animal clinic in Rishon. Aric joined Teva’s R&D in 2001, starting in the non-clinical safety unit, followed by working as a “project leader”, overseeing project development from early preclinical studies advancing to clinical stages. Currently, Aric is heading the pharmacology department and working with a team of scientists to provide in-depth insights on drug candidate’s activity and potential therapeutic benefits.

Arik Zur, PhD | Project Director at BiolineRx

Arik Zur is currently a project director at BiolineRx, leading drug development program of an immuno-oncology asset in clinical stages. Previously Arik lead all clinical pharmacology activities at BiolineRx and served as a medical monitor of a first in human study in patients with solid tumors. Prior to joining BiolineRx he was a clinical pharmacology manager at Teva. Arik research interest and experience along the years is in pharmaceutical sciences and pharmacogenomics. He was a postdoctoral fellow at the University of California in San Francisco (UCSF) and the FDA office of clinical pharmacology where he studied brain drug distribution and biomarkers for drug-drug interactions. He acquired his PhD from the departments of pharmaceutical sciences and human metabolism at the Hebrew University. Arik also holds master’s degree in clinical pharmacy as well as in business administration from the Hebrew university and is a registered pharmacist in Israel. Speakers - 2019

Mr. Assaf Barnea | CEO Sanara Ventures

Mr. Assaf Barnea is a seasoned entrepreneur and venture professional, with extensive, multidisciplinary experience in building innovation platforms and leading commercialization processes in healthcare. He leads Sanara Ventures, a healthcare innovation fund backed by Phillips and Teva.

In addition to leading Sanara, Mr. Barnea chairs the Life Science Advisory Board at The Israel Export Institute, on behalf of the Israeli government, promoting and advancing the export of Israeli technologies in the medical, biotech, pharma and digital fields in global markets. A valued consultant, Mr. Barnea also advises the World Bank’s IFC venture capital team and is a co-founder of the IFC’s Tech Emerge initiative; a unique acceleration platform that connects healthcare startups from around the world with leading corporations and hospitals in emerging economies. On December 2018, Tech Emerge Health has won the world bank group president’s award for innovation.

Formerly, Mr. Barnea was one of the founders of CardioSense, a medtech startup company that developed a probe for early shock detection in various medical settings. Before lending his multidisciplinary acumen to Sanara Ventures, Assaf served as CEO of Kinrot Ventures, spearheading its acquisition by Hutchison Water in 2012. Prior to this, he headed business development at Mekorot, Israel’s national water company, where he oversaw the establishment of WaTech, the Entrepreneurship & Partnership Center for Water Technologies. For his accomplishments in both Mekorot and Kinrot, he received the Cleantech Group’s Innovation Hero Award in April 2013, which recognizes individuals whose commitment, drive and passion have made a tangible difference for innovation in general and specifically for many start-up companies.

Previously, Mr. Barnea served for four years as director of business development at Comverse, where he also co-chaired the Mobile Marketing Association. A unique highlight in Assaf’s story is his former stint as a college basketball player at New Jersey’s Seton Hall University, where he won the Big East championship against Georgetown. He went on to play professional basketball in Israel’s national league, while completing multiple academic degrees. A certified lawyer, Mr. Barnea holds both law and business degrees from the Interdisciplinary Center in Herzelia, as well as a BA in political science and psychology from Tel-Aviv University.

Avinoam Sapir, MBA | SVP Cluster Manager Teva Israel, Turkey, Ukraine & Africa

Avinoam joined Teva in 2002 and spent his first years in the company in financial management positions and was head of the strategic customers unit in Teva Israel. In 2007 Avinoam was appointed to serve as CEO of SLE, Teva Israel's distribution company. During his time as CEO, he initiated the establishment of Teva's logistic center in Shoham and headed this project. This logistic center is one of the largest of its kind in the world. From 2011, Avinoam served as Vice President of Business Development at Teva's Headquarters. In this role he was responsible for a range of activities related to the company's global business development, focusing on mergers and acquisition activities.

In 2013 he was appointed CEO of Teva Israel, responsible for marketing, sales and distribution activities for Teva throughout Israel. In 2016, Avinoam was appointed SVP for the region including Africa, Middle East & Ukraine. Avinoam holds a BA (Summa Cum Laude) in Economics and Logistics from Bar Ilan University and an MBA from Tel Aviv University. Before joining Teva, he established and managed a start-up media company and, prior to that, served for a decade as a commanding officer in the IDF. Speakers - 2019

Ms. Cohav Nir | Senior Manager, Sourcing & Employer Branding at Teva Pharmaceuticals

15 years of experience partnering with business leaders to achieve business goals through the implementation of effective talent acquisition strategy. Experienced with mentoring and coaching recruitment professionals, successfully developing and managing talent supply pipelines, and understanding and communicating EVP (employer value proposition). Strong background in Talent Acquisition methodologies, information systems, KPI's etc. Specialized in the medical, pharmaceutical and multi-disciplinary industry.

Daniella Gutman, PhD VP, Generic R&D, and site head Israel & Hungary, | Teva Pharmaceuticals

Education: Education: BSc and MSc in Chemistry Technion Israel, PhD in Chemistry, Weizmann Institute Israel, Post Doctorate in Chemistry, ZFL CIBA-GIEGY Basel, Switzerland Experience: 27 years of R&D experience in pharmaceutical industries. Join TARO pharmaceutical in 1992, served in several roles with increasing responsibility in the R&D. joined TEVA in 2007 leading the Israel generic R&D. in addition was responsible of the R&D of the international markets, gained experience in the different regulations and different market's needs. Experience in development of API and DP, regulations, management and transformation of organization aligned with organization strategy.

Daphna Laifenfeld, PhD | Chief Strategy Officer, Ibex Medical Analytics

Dr. Daphna Laifenfeld is Chief Strategy Officer at Ibex Medical Analytics, a digital health company using AI and Big Data to create a new modality in cancer diagnostics and personalized treatment selection. In this role, Daphna drives the overall diagnostic strategy and execution including clinical utility elements, strategic partnerships, as well as regulatory and IP aspects. In addition, Dr. Laifenfeld is co-founder and CSO of Genetika+, developing a platform to enable personalized medicine approaches to treatment recommendations in CNS. Prior to joining Ibex and co-founding Genetika+, Daphna served as Head, Personalized Medicine and Diagnostics, at Teva's Global R&D, where she led the strategy and delivery of personalized medicine solutions, from defining the need and clinical relevance, through to scientific execution, and on to commercialization. Before Teva, Dr. Laifenfeld engaged in biomarker and diagnostic development activities within the pipeline of multiple top-10 pharma and fortune 500 companies. She served in several roles with increasing responsibility at Selventa, a system's biology company focused on personalized medicine, and was appointed as Global Head of Diagnostics, where she was responsible for company-wide diagnostic development strategy, in addition to overseeing external partnerships and collaborations. In academia, Dr. Laifenfeld studied molecular pathways and pharmacogenomics in CNS, including a focus on the biology underlying Alzheimer's disease in Prof. Rachael Neve's lab at Harvard University, and on pharmacogenomics of Major Depression therapeutic response at Prof. Ehud Klein's lab at the Technion. Dr. Laifenfeld received her PhD from the Technion – Israel Institute of Technology. Speakers - 2019

Ms. Daphna Murvitz | Co-founder and CEO, 8400 – The Health Network

With a track record in cross-industry and cross-sector leadership, including hi-tech, bio-med and services, within the private, government and non-profit sectors, Daphna is a change leader and a people-driving executive, who combines vision with effective implementation and collaboration skills to reach ambitious impact. She was previously EVP of Beta O2 Technologies, CEO of Israel Venture Network (IVN) , Director of global operations at Software Technologies , held prior executive positions in Strauss & Co. and FCO-FedEx and served as a commercial attorney at Shekel & Co, law firm. She holds a L.L.B and a BA from Tel Aviv University and is certified as an executive coach and a corporate director.

Dov Tamarkin, PhD | CEO at Tamarkin Ventures

Dr. Dov Tamarkin is a senior pharmaceutical executive, with over thirty years of experience. He holds a Ph.D. degree in chemistry from The Hebrew University of Jerusalem, Israel; and he is the inventor of over a hundred patents in the pharmaceutical field. In 2003 he co-founded Foamix Pharmaceuticals (Nasdaq:FOMX). He served as CEO of the Company, incepted the company’s drug delivery technology, led the development of multiple dermatological products, including Minocycline Foam, which has successfully been tested in Phase 3 clinical trials. In 2014, Dr. Tamarkin made Foamix a multinational company with operations in Israel and the US and led its listing on Nasdaq. Prior to Foamix, Dr. Tamarkin held executive positions at Teva Pharmaceuticals, Portman, PowerPaper and TPI. Since his resignation from Foamix in 2017, Dr. Tamarkin acts as a strategic advisor and Board member in pharmaceutical companies worldwide.

Efrat Shalom Berensohn LL.M Senior Director, General Counsel, Global R&D, | Teva Pharmaceuticals

Efrat holds an LL.M from Boston University, LL.B cum laude from the Interdisciplinary Center Herzliya and BA in Sociology & Communication from Haifa University. Efrat has been with Teva's legal for five years supporting the Global R&D activities, Heading the legal team responsible for providing legal support for all R&D activities. Prior to joining Teva, Efrat served as an Associate Technology Transactions and Senior Technology Transactions for more than five years at Harvard University's office of Technology Development where she was responsible for facilitating transfer of cutting-edge Harvard-developed innovation from lab to global public sphere through legal work (e.g. licensing, sponsored research and new venture agreements). Prior to joining Harvard Efrat held an in-house counsel positions both in a drug development company based in Boston US (Epix Pharmaceuticals) and in an Investment and holding private group specializing in energy, real estate, infrastructure and communication based in Israel (Petrolgaz Group). Speakers - 2019

Udi Eyal Fima, PhD, MBA

Dr. Fima was the President & CEO of Enlivex, and has served on its board of directors since March 2014 through October 2018. Previously, from 2005 through 2015, Dr. Fima was Vice President, Product Development, COO and then CEO of PROLOR Biotech. PROLOR Biotech was listed on NYSE in 2010 and then acquired by OPKO Health in 2013 for $560 million, the largest biotech acquisition in the history of Israeli biotech. Dr. Fima also co-founded NatSpears Ltd., a company specializing in cancer therapeutics, and served as its CEO from 2002 to 2005. Prior to founding NatSpears, Dr. Fima was a research fellow at the Immunology Department of Ben-Gurion University in Israel from 2000 to 2002, where he researched the involvement of signal transduction in breast cancer. Dr. Fima received his Ph.D. in immunotherapeutic protocols and cytokine regulation from Ben-Gurion University's Medical School in Israel, and an M.B.A. from the Ben-Gurion University's Business School. Dr. Fima is the former National and Olympic coach of the Israeli Taekwondo team, leading the team to medals in world championships of 1998 and 2000, and in European championships in 1997, 1998 and 1999.

Elijahu Berkovich, PhD | Products Cluster Leader, Clexio Biosciences LTD.

Elijahu Berkovich is a scientist with over 10 years of pharmaceutical industry experience. Elijahu brings the unique ability to identify a medical problem, identify solutions, develop concepts and test them quickly in preclinical models and in human. Prior to his role as products cluster leader at Clexio, Elijahu was a Senior Director at Teva Pharmaceuticals, holding various positions within Global R&D and Medical Affairs. In his last position at Teva, he was part of a leadership team that built an efficient engine for organic growth (New Therapeutic Entities), implementing a multidisciplinary approach to create tailor made medical solutions to meet particular unmet needs. This lead to enhancing the Teva Specialty R&D pipeline in addition to selling/spinoff of projects for further development by new startup companies. Prior to that, Elijahu held a medical/scientific affairs positon specializing in neurodegenerative diseases (Parkinson’s disease). Elijahu holds a bachelor degree in Biochemistry and Science (with highest distinction) from the Hebrew University of Jerusalem and a M.Sc. and Ph.D. (with distinction) in Molecular and Cellular Biology from the Weizmann Institute of Science. Elijahu completed his Post-doctoral fellowship in the Hematology/Oncology Department at St. Jude Children’s Hospital, Memphis, TN, where he focused his research on DNA damage response and published peer-reviewed articles in top tier journals.

Eran Harary, MD Senior Director, Global Clinical Development, | Neuropsychiatry, Teva Pharmaceuticals

Eran is a psychiatrist with over 13 years-experience in the pharmaceutical industry in senior managerial positions, experienced in Lifecycle Management of pharmaceuticals from concept through all development phases and in strategic planning and execution of both clinical and commercial global operations. Eran did his residency in psychiatry at Sheba (Tel Hashomer) Medical Center in Israel where he later served as a Senior Psychiatrist. In 2005 Eran moved to the pharmaceutical industry where he served in various leadership positions including Country Medical Director for Lundbeck in Israel, Country Medical Director for Pfizer in Israel, Senior Director for Neuroscience & Primary Care Portfolio Development (Emerging Markets and Established Products Business Unit) in Pfizer Headquarters in New York and most recently as Senior VP Clinical Strategy at Alcobre Pharma. Eran is serving as the Clinical Lead for the clinical neuropsychiatric development projects in Teva Global R&D. Speakers - 2019

Ms. Eti Raihenshtein |Director, Talent Acquisition International Market, Teva Pharmaceuticals

Eti Raihenshtein is Teva International Market Talent Acquisition Director In her role, she is responsible for developing talent acquisition strategy and building staffing capabilities to ensure we have the pipeline of talent needed to meet Teva's current and future goals. Eti holds 20 years of comprehensive experience building and leading world-class innovative teams. During her career Eti had worked as Talent Acquisition leaders in big corporates such as Strauss Group and NCR and with this experience, she bring a broad view and insights on the labor market, future workplace and market demand for talents

Hilla Kedar, PhD | Senior Director, Head of Nonclinical Safety, Teva Pharmaceuticals

Hilla holds a PhD in Zoology from Tel Aviv University, a MSc in Molecular Neuroscience from the Weizmann Institute of Science and a second MSc in Applied Toxicology from Surrey University in the UK, which she completed during her years at Teva. Hilla is a certified Toxicologist, with over 12 years of experience in toxicology and drug development. Prior to working at Teva Hilla worked in Wisebands, and Israeli start up developing a medical device, and in parallel was a lecturer in the Open University in Israel. Hilla is busy spreading the 'word of toxicology' and in building bridges of collaboration within Teva and with academia.

Ianai Fishbein, PhD | Associate Director, Nonclinical Development, Teva Pharmaceuticals

Dr. Ianai Fishbein is currently a scientist and a team leader at Teva's innovative R&D (Natanya). In this capacity he is responsible for the establishment of cellular and molecular biology assays for new compounds development and discovery. During his postdoc at the University of California San Francisco (UCSF), he studied the molecular mechanism responsible for the correlation between Gaucher disease mutations and Parkinson's disease. He demonstrated that in the presence of the Gaucher mutation, the aggregating protein Alpha-Synuclein is poorly metabolized by neuronal cells. Ianai acquired his PhD at the Weizmann institute in the department of neuro biology. His theses dealt with the correlation between neuronal bio electrical activity and neuronal viability. Speakers - 2019

Iris Beck-Codner, MBA Executive VP, Global Brand | & Communications, Teva Pharmaceuticals

Mrs. Beck-Codner, is the Executive Vice President, Global Brand & Corporate Communication at Teva since April 2013. Prior to joining Teva, Mrs. Beck-Codner served as Group CEO, McCann Erickson Israel, where she was responsible for overseeing the Media, Digital and Creative Advertising business. Prior to that, Mrs. Beck-Codner served as Chief Marketing Officer at Orange Telecommunications in Israel (NASDAC PNTR), overseeing Brand Proposition, Product & Services, Customer Retention & Acquisition, and Content Generation. Between 1996 and 2002 she held various executive positions with Israel, the last being General Manager of the Home & Personal Care business. Mrs. Beck-Codner has a Masters degree in Marketing & Business Administration from the University of Bar Ilan, Israel and a BA in Economics, from the University of Haifa, Israel. Graduate of THNK, Amsterdam, school of Creative Leadership and social entrepreneurship.

Irit Carmi-Levy, PhD | Project Director at BioLineRx

My current position is Project Director at BioLineRx. BioLineRx is a clinical-stage, publicly-traded biopharmaceutical development company based in Modi'in. As a project director I lead the strategic planning of the projects and oversee all aspects of scientific, R&D, CMC, regulatory and clinical activities, timelines and budgets for several clinical and pre-clinical programs. My role involves management in matrix organization, initiating /managing cross-functional teams and multi-disciplinary projects. Responsibilities furthermore include due diligence of projects and defining the portfolio strategy for the immunology arm and areas of interest for the scouting team, presentations for BOD, JSC / JDC and advisory boards, steering meetings with projects’ inventors / PIs, participation in acquisition integration and alliance management activities. Before that, in 2010-2014, I was a post-doctoral fellow at the Institut Curie (Paris, France). As a post-doc, I conducted research in the fields of systems immunology and integrative biology of human dendritic cells and T cells at the department of immunology and cancer. I received my PhD from the Hebrew University in Jerusalem, where the focus of my research was the unique regulation of transcription factors in Mast Cells and the identification of a novel “second messenger” molecule -Ap4A.

Ms. Irus Huminer | Director of the Department of Business Entrepreneurship, MoAI

Irus is responsible for tax issues and economic and business-related aspects in the Ministry of Aliya and Integration.

Itai Kela, PhD, MBA Head of Healthcare and Biotechnology sector | in the Israel Innovation Authority

Dr. Itai Kela is the Head of Healthcare and Biotechnology sector in the Israel Innovation Authority (IIA), in charge of nurturing and developing innovation resources to support and accelerate the Israeli life science industry and its ecosystem. Former CEO and co-founder of Cell Gene Actor, a CAR T cell technology company. Dr. Kela held a variety positions in other life science companies, including NRGene, Stem Cell Medicine and Protalix (NASDAQ:PLX). He holds an MBA, and a PhD in cancer genomics from the Weizmann Institute of Science. Dr. Kela was a postdoc fellow at Stanford University, where he specialized in personalized medicine and oncology. Dr. Kela won The Center of System Biology Award from the Weizmann Institute of Science. Speakers - 2019

Itamar Yaron-Enden, MSc, MBA Senior Director, M&A and Global Alliances, | Business Development, Teva Pharmaceuticals

Itamar is leading M&A and alliances activities as part of Teva's global Business Development team. Itamar has been with Teva for 6 years, in Strategy and BD roles. In recent years Itamar led several buy and sell side transactions, most recently the divestitures of the Teva Women Health business for $2.5B and the Israeli Tevadaptor medical device business. In his current role, Itamar led corporate M&A processes in Specialty Pharma, Generic and biotech from target identification, to valuations and deal execution. Itamar also led several partnership initiatives towards expanding Teva's global footprint and opening new franchises in new markets. Prior to joining Teva, Itamar spent couple of years in Strategic and management consulting positions as part of Shaldor Ltd, and in Cancer research as part of the Weizmann Institute of Science. He holds a B.Sc. in Medical Sciences from the Tel-Aviv University (Cum Laude), a M.Sc. in Life Sciences from the Weizmann Institute of Science and an Executive MBA from the Recanati School of business at the Tel-Aviv University.

Dr. Jennifer Dreymann | Director, Translational Medicine Expert, Teva Pharmaceuticals

Dr. Jennifer Dreymann is a Translational Medicine expert at Teva for two years where she plans, designs and drives biomarkers strategy and execution. She is the main representative for all oncology projects and works also for other therapeutic areas as asthma or coeliac disease. Before joining Teva Jennifer worked for 15 years at Sanofi in France where she was in charge of biomarkers plans from early discovery to late development stages. Jennifer received her Pharm D from Paris V University and then pursued a 4 years of residency in Paris hospitals to complete a specialization in pharmacogenetics, working on the genetic expression of circulating tumor cells.

Jonathan Solomon, MBA | CEO at BiomX Ltd.

Prior to his role in Biomx, Mr. Solomon was a co-founder, president, and CEO of ProClara (formerly NeuroPhage), which is pioneering an approach to treating neurodegenerative diseases. Under his leadership, the company raised more than $100 million and launched an ongoing clinical trial related to Alzheimer’s disease. Prior to that, he was selected to participate in the elite Israeli Defense Forces ‘Talpiot’ program, graduated as class valedictorian, and served for 10 years in a classified military unit. Mr. Solomon holds a B.Sc. magna cum laude in Physics and Mathematics from the Hebrew University, an M.Sc. summa cum laude in Electrical Engineering from Tel Aviv University, and an M.B.A. with honors from the Harvard Business School. Speakers - 2019

Karin Mayer Rubinstein, MBA | CEO & President of IATI

Karin Mayer Rubinstein is the CEO & President of IATI, Israel’s Umbrella Organization of the High-tech, Life Science and other advanced technology industries, with hundreds of paying members from every level and aspect of the ecosystem, including Venture Capital Funds, Israeli R&D Centers of Multinational Companies, Start-Ups, Incubators & Accelerators, leading global Stock Exchanges, Tech Transfer Organization, Academic Institutions, Innovation Centers, Hospitals, Municipalities, service Providers and more. Through this broad range of members, IATI connects Israel’s tech ecosystem, provides solutions and support at all levels, and integrates the various sectors of the industry with strategic and ongoing governmental goals. Prior to her current position, Karin served as a senior partner and managing director of business development in leading commercial law firms. Karin is a member of steering committees and a keynote speaker of many leading global events and conferences around the world. She is a member of the board of Governance of Tel Aviv University, a Director in the Israel-America Chamber of Commerce, a member of the 5×2 Initiative's Steering Committee, a Council for the Advancement of Women in Science and Technology of the Ministry of Science and Technology, an Honorary Ambassador of GISEP, and more. Karin is a keynote speaker at many leading global conferences. She regularly sits as a jury member in leading technology competitions and awards worldwide. Karin holds a BA in Economics, an LLB and an MBA from Tel-Aviv University. Karin was named, twice in a row, as one of the Top 100 Influential Young Business Persons in Israel by Forbes Magazine, as well as one of the Marker's Top 40 Leading Young Business Persons.

Levana Volovsky, MSc | Director, Global Regulatory Affairs, CNS, Teva Pharmaceuticals

Levana has worked in Teva for 16 years in the Regulatory department in the position of Global Regulatory Leader for various projects at different stages of development and leads the regulatory strategy for major submissions globally. Levana has a Bachelor's degree in Chemistry and a Master's degree in Quality Assurance and Reliability, both from the Technion, Israel Institute of Technology. Before working in Teva, Levana worked in 2 other pharmaceutical companies in different positions, so today Levana has above 25 years of experience in the pharmaceutical field in Regulatory, RA CMC, QA and Clinical units.

Liat Duani, MBA | Senior consultant, Diva Keren Creative HR

Senior consultant at Diva Keren Creative HR who brings over 20 years of experience in senior HR positions. Diva Keren Creative HR is an Israeli Executive Search company that has been operating for more than 15 years within the Life Science market, specializing in Search and Recruitment for executive and senior management positions both locally and globally. The company’s sector specialisms include Pharmaceutical, Medical Device, Biotechnology, Investment funds, Research Institutes, Diagnostics, FoodTech and AgroTech and its unique professional recruitment process is designed to fill executive and senior managerial positions in the organization efficiently and professionally, and in a comprehensive and discreet manner. Liat brings vast experience in several industries such as bio-tech, high-tech, financial and industrial both in public and private companies. She is an expert when it comes to recruitment, building winning staffs and leading organizational processes. Liat serves as an in-house senior consultant at Diva Keren Creative HR and leads Executive Search projects. She also devotes her time to HR and Organizational Development consultancy, with emphasis on developing leadership and vision, management skills, team development and change management. Liat has a BA in Psychology and an MBA specialization in Organizational Behavior from the University of Tel Aviv. She is also a certified group facilitator from the Institute of Group Facilitators Tzipori. Speakers - 2019

Ms. Limor Lior | Organization Development Manager & HRP at Pluristem Therapeutics

41 years old, married and a mother to 3 magnificent boys, leaving in the north. I have a bachelor's and master’s degree in Biotechnology Engineering. I started my professional way in Pluristem 15 years ago, when the company just initiated. Pluristem is a cell therapy company, developing and manufacturing placenta cells derived products. The company is located at Matam, Haifa and employs 170 employees. At the beginning I was part of the research team and Head of the Pre-Clinical Experiments. When the Development department initiated, I started my first managing role as a Development Team Leader. Later on I made another transition and became the Production Manager. During this period, we built our new production plant - a state of the art facility in the cell therapy world, and significantly expanded the department and the company head count. From the management world and after 4 years as the Production Manager,I made a significant switch to the HR -Human Resources and established the Organization Development world which consists of management development and internal communication. In addition, I work with the Research, Development and Clinical Departments as HRP-HR Partner. In my position I serve as a focal point to employees and managers with a biological, engineering or medical background, departments that in the cutting edge technology and our business, and the different management levels. I have the opportunity to influence and promote our world, and this time with a different perspective, while I have a deep introduction with the whole organization, professional knowledge with the biotech world, and personal experience as a manager.

Lizi S. London, MSc | Partner and Co- Managing Director of Nisha Executive

Lizi is a Co-founder of two “exit” companies and has a vast academic background (M.Sc., Biotechnology, B.A., Pharmacology, B.Sc., Agriculture), and over 18 years of experience in Executive Search. Prior to Nisha, Lizi served in executive marketing and sales positions in leading organizations in the Israeli health care industry. Lizi is a partner at Nisha and the Executive Director of two business units; In 2000, Lizi established the Biomed business unit which has evolved into Israel’s leading recruitment agency in the field of life sciences. In 2007, she founded the Cleantech & Infrastructure business unit. Lizi has an extensive experience in placing senior executives such as CEOs and Technology, Operation, Business and Regulation VPs. She has in depth familiarity with a wide spectrum of tech organizations.

Mr.Mati Gill Head of Government Affairs, Corporate & International Markets, | Teva Pharmaceuticals

Mati is the Head of Government Affairs, Corporate & International Markets at Teva Pharmaceutical Industries, a global leader in generic and specialty pharmaceu ticals that delivers high -quality medicines to 200 million people around the world every day. Maty previously served as Chief Operations Officer (COO) of the Teva Global Legal Group between 2011-2016 and serves as a member of the Board of Directors of Sanara Ventures. He is also a licensed Lawyer and served as the Executive Director of the Australian Israel Leadership Forum. Until March 2009, Mati served as Chief of Staff of Israel's Minister of Public Security Mr. Avi Dichter, a position in which he was in charge of management of the

Minister's public agenda and office, and advised on professional, political, communications and international affairs. Mati is an active social entrepreneur in the Israeli community. He co-founded and leads the "Sanhedrin Forum" for young Israeli professionals. A reserve officer at the rank of Major in the IDF, Mati served as Operational Liaison Officer with United Nations Peacekeeping Forces in Lebanon and the Golan Heights and with the United States Army. Speakers - 2019

Moran Grossman, PhD | Senior Scientist at MabTrix

I graduated the molecular biochemistry track at the Technion at 2004. Then, I was accepted to the Weizmann institute of Science (WIS) for my Master's degree in chemistry where I joined the labs of Nobel Prize winner, Prof. Ada Yonath, at the department of Structural biology and Prof. Mattityahu Fridkin in the department of Organic chemistry. At 2007, I started my PhD research at the lab of Prof. Irit Sagi at the department of structural biology. My studies focused on biophysical and structural studies of enzymes responsible for extracellular matrix remodeling called the matrix metalloproteinases (MMPs). During my studies I established a strong collaboration with the lab of Prof. Martina Havenith in Ruhr University in Germany, and together we pioneered measurements of correlated protein-water dynamics during enzymatic reaction. This strong collaborative work contributed significantly to the establishment of the RESOLV (Ruhr Explores SOLvation) cluster of excellence on 2012, funded with 28 Million EUR by the German Research Foundation (DFG). Following this great collaboration, I was invited at 2013 to Prof. Martina Havenith’s lab as a post-doc student funded by the RESOLV cluster, and later by the Alexander von Humboldt foundation. I was also rewarded a postdoctoral award for advancing women in science. When I completed my post-doc research at 2016, I was offered the opportunity to found a startup company, MabTRix, developing anti-MMP-9 antibodies based on patents from the lab of Prof. Sagi to control ECM degradation in inflammatory indications.

Moshe Ben-David, PhD | R&D Director, Ukko

Moshe Ben-David is the R&D Director at Ukko, an early-stage Israeli-American startup focusing on food allergies and sensitivities. Ukko uses patient data, machine learning and AI to guide the engineering of food proteins that can be incorporated into food products, plants or therapeutics. Moshe established the R&D division of Ukko in Israel, and he is currently managing and leading the R&D team. Before joining Ukko, Moshe conducted research focusing on protein engineering and structural biology in world-leading research groups. He received his MSc and PhD from the Weizmann Institute and did a postdoctoral fellowship at the University of Toronto. During his postdoctoral studies he served as the Regional Manager of ScienceAbroad in Toronto.

Mr. Nadav Eshkol | Technology and Process Development Manager, Pluristem Therapeutics

Nadav Eshkol is the Technology and Process Development Manager at Pluristem Therapeutics, Israel. Holding a Bachelor’s degree in Biotechnology from the Technion – Israel Institute of Technology. Nadav has been working in Pluristem in process engineering and process development areas for more than 6 years, expertise in bioreactor technology, process development and scale up, and technology transfer to pilot and production. Previous to Pluristem, Nadav has worked for 5 year in the semiconductors industry, as a senior photolithography process engineer in Tower-Jazz Semiconductors.

Speakers - 2019

Neta Kela-Madar, PhD | Head of Innovation and Entrepreneurship Center, SCE

Dr. Neta Kela has more 15 years of experience in global business development, innovation and entrepreneurship education in advanced healthcare technologies. Dr. Kela has extensive experience in developing innovation and disruptive technologies in life science industry with proven clinical background in immunology, immunotherapy and drug development from the Stanford University (CA, USA). Dr. Kela holds a PhD in immunology from the Weizmann Institute of Science and won The McCormick Award from the Stanford University. Dr. Kela serves as the CEO of the EIC (Entrepreneurship and innovation Center) and the head of Innovation and entrepreneurship program and senior faculty in SCE engineering College.

Nir Shapir, PhD | VP Biologics, CMC Biosimilars, Teva Pharmaceuticals

PhD from Hebrew University of Jerusalem; Faculty of Agriculture, Food and Environmental Quality Sciences. Post Doc and Research Assistant Professor at the Biotechnology and Biochemistry departments of the University of Minnesota, working on the isolation of several genes and related enzyme expression, purification and characterization. Group Manager leading a "Discovery and Technology" team at Beckman Coulter, Minnesota, assessing new disease related biomarkers, innovative immunoassay technologies and developing an IVD immunoassay. Moreover, leading a multidisciplinary, multisite strategic project for the development of a Point-of-Care device using newly developed innovative immunoassay technology. SVP and Site Head at Medgenics Medical, leading the development of an ex-vivo gene therapy platform for the treatment of protein deficient diseases, and bringing the technology to successful clinical trials both in Israel and the US. My current position at Teva is "VP Biologics, CMC Biosimilars" leading the early stage development of Biosimilars; from cell-line development and clone selection through manufacturing and purification processes development.

Ofer Spiegelstein, PhD | VP, Innovation Initiatives, Teva Pharmaceuticals

Ofer holds a BPharm in Pharmacy, MSc Pharm in Clinical Pharmacy and PhD in Pharmaceutical Sciences/Biopharmaceutics from the Hebrew University of Jerusalem. In 2003, after four years of postdoctoral research in the US, Ofer joined Teva's specialty R&D working in preclinical research, specifically focused on toxicology and ADME. In 2007 Ofer moved to clinical research and led the phase-1 & clinical pharmacology group. Over 11 years Ofer has done much to develop the clinical pharmacology discipline and capabilities to global pharmaceutical industry R&D standards. During this period, more than 50 programs were supported spanning multiple therapy areas, indications, product types and routes of administration. During 2018 Ofer started a new position looking at innovation, particularly within the Israeli ecosystem. Speakers - 2019

Omri Amirav-Drory, PhD | Founding General Partner, Tech.bio

Dr. Amirav-Drory is the founding general Partner of Tech.bio, a fund dedicated to empower scientists to become entrepreneurs and start transformative companies at the intersection of technology and biology. Prior, he was the head of corporate development at Twist Bioscience (a next generation DNA synthesis company). Before that he was the founder & CEO of Genome Compiler Corp, a Synthetic Biology venture (acquired by Twist Bioscience 2016). Prior to starting his company, Dr. Amirav-Drory was a Fulbright postdoctoral research fellow at Stanford University School of Medicine & HHMI, performing Neuroscience research using Structural and Synthetic Biology methods. Dr. Amirav-Drory received his Ph.D in Biochemistry from Tel- Aviv University for Biochemical and Structural studies of membrane protein complexes involved in bio-energetics.

Ophir Shahaf, LL.B., MBA | VP Business Development at eHealth Ventures Incubator

Trained as a corporate lawyer in Tel-Aviv University and completed an MBA in finance at the Stern School of Business (NYU). As part of the founding team at Hadasit Bio (HBL), was part of the company’s IPO and led the company during 5 subsequent rounds of financing (totaling approx. $ 25 M), via Conv. Bonds, PIPE's, rights and secondary offerings. The HBL portfolio companies have raised under his guidance an additional $ 20 M including 6 strategic partnerships and investments from some of the leading VCs and institutional investors in Israel. Completed an ADR listing on the OTC and successfully completed 5 clinical trials (up to Ph. IIb) as well as various regulatory approvals within the portfolio. Leadership of a portfolio of biotechnology companies through these challenges has strengthened a solid bio/financial skill that was acquired while serving as part of the founding team at Clal Biotechnology - Israel’s largest investor in life sciences and as VP BD at Protalix, traded on Amex. Also served as CEO of a Med. Dev. company in the Ultrasound space that was taken public on NASDAQ. Currently serving as VP BD of a leading Digital Health investor, responsible for deal flow, due diligence, negotiations and other operational aspects of the holding company and the portfolio. A native English speaker with legal, financial and scientific education, and 20 years of experience working within the life science industry (BD and CEO of private / public / institutional co.). Based in Tel-Aviv, father of 3, enjoys long distance running, skiing and cooking.

Orit Stern-Maman, B.Sc. Pharmacy VP, Head of Pharmacovigilance & Patient Safety, | Teva Pharmaceuticals

Orit Stern Maman is V.P. Head of Teva's Global Patient Safety & Pharmacovigilance (PhV). PhV is the science of collection, detection, assessment, monitoring and prevention of adverse events with pharmaceutical products. As head of the PhV unit, she is responsible for defining and implementing patient safety policies and systems and ensuring compliance with relevant global and local regulations pertaining to patient safety in Teva markets worldwide. Prior to taking on this role, she served as Head of the Medical Scientific Unit and as the Head of Data Management & Global Operations. Orit joined Teva in 2000 as a PhV Associate after obtaining her B.Sc. in Pharmacy from the Hebrew University in Jerusalem. Speakers - 2019

Pini Orbach, PhD | Head of Pharma Division, Arkin Holdings

Dr. Pini Orbach joined Arkin Holdings in 2010 as Head of its Pharma Division and since 2016 he is also managing Arkin Bio Ventures , the investment arm of Arkin Holdings, which specializes in pharmaceutical and biotechnology innovations . Dr. Orbach is a member of the board in several of its pharmaceutical companies, including UroGen Pharma (NASDAQ, URGN), Metabomed Ltd., Censa Pharmaceuticals, BioSight Ltd. and RedPin Theraputics from which he shares his extensive hands-on drug development and business experience. He originally gained his foundation in US based companies such as, Arisaph Pharmaceuticals and Epix Pharmaceuticals (NASDAQ, EPIX), as well as Israeli-based companies such as, cCAM BioTherapeutics - a cancer immunotherapy company, which was sold to Merck in 2015 for $605M. He holds a Ph.D. from the Department of Physiology and Functional Genomics, University of Florida, and was a postdoctoral fellow at the Cardiovascular Research Center, Harvard Medical School - Massachusetts General Hospital.

Reut Shema, PhD | Associate, aMoon

Dr. Reut Shema is an associate at aMoon, a leading healthtech and life sciences venture fund. Previously, Reut was VP Business development and scientific advisor at greenfield partners, a TPG growth investment platform. She also served as an advisor to several prominent international investors and co-founded a company in the healthcare field. Reut has over 10 years of experience in cutting edge research and has won numerous grants and awards for her work. She was a postdoctoral fellow at the Broad Institute of MIT and Harvard, where she led a project team to develop a novel platform for evaluating therapeutics for psychiatric diseases. Her study of ageing and neurodegenerative disease has led to the development of a novel in vivo screening method and was published in the high impact journal PNAS. Reut completed her PhD in Weizmann Institute of Science, where she studied Long term memory maintenance in the brain. Her work has contributed greatly to the field and is summarized in three papers, including two in the prestigious journal Science. She holds a B.Sc. in Biology and psychology (Magna Cum Laude) from Tel-Aviv University.

Roni Mamluk, PhD | CEO, Ayala Pharmaceuticals

Roni Mamluk, PhD is a senior biopharmaceutical executive with 14 years of experience in drug development companies and background in all aspects of R&D, general management and fundraising. Prior to Ayala Roni was at Chiasma (NASDAQ: CHMA) a biopharmaceutical company focused on orphan diseases where she fulfilled multiple positions including CEO (2013-2015). She is an inventor of their oral delivery technology, led the development of their lead product through all stages of development, including NDA submission. She was a key player in fundraising for the company including several private financing rounds and led a $70 million crossover financing and a successful IPO of over $100 million in 2015. Roni is now a board member at Chiasma. Prior to that she was heading preclinical development of an oncology product at Adnexus (which was later acquired by Bristol-Myers Squibb (NYSE:BMY)) in Waltham, MA and prior to that did her post doc at Children’s Hospital/Harvard Medical School in the field on angiogenesis. Roni received her PhD, summa cum laude from the Hebrew University in Jerusalem. Speakers - 2019

Shmuel Hess, PhD | CEO, Enlivex Therapeutics

Dr. Hess received his PhD in Pharmaceutical Science from the Hebrew University, Israel and was a research fellow at Harvard-MIT Health Sciences and Technology (HST) Dr. Hess has gained numerous patents and publications in peer reviewed scientific journals. Prior to joining Enlivex Dr. Hess served as the CEO of Valin Technologies since inception overseeing the execution of the company activities and its achievements including the development and technology transfer of several biologics and the in-licensing and acquisition of three early stage innovative projects and the further drug development process. Prior to joining Valin Technologies Dr. Hess was founder and CEO of ActivePx, a biotech company engaged in the development of oral available peptides for the treatment of pain. Following which he served as associate global operations at Scigen LTD (NASDAQ: VBIV), where he supported the establishment of a state of the art vaccine manufacturing facility for SciBvac® as well as a biologic manufacturing facility in India. Dr. Hess is co-founder and chairman of ScienceAbroad an NGO dedicated to encouraging and support the return Israeli scientist from abroad. Dr. Hess has experience with drug development, process development and scale-up of biologics and GMP manufacturing.

Shoshi Friedman B.S.N R.N | VP, Global Clinical Operations, Teva Pharmaceuticals

Holds B.S.N R.N from the Hebrew University. Joined Teva 19 years ago and served in various roles within the Specialty R&D: Clinical Data Quality Control, Medical Monitoring and more than two years ago leading Global Clinical Operations. Responsible for the planning and execution of Teva’s R&D global development and clinical supply of the specialty programs across all indications and all phases (excluding healthy volunteers studies) in terms of cost, quality, timeliness and efficiency, while assuring patient safety and data quality and integrity.

Tal H. Hasson, PhD Associate Director, Analytical Development, Specialty CMC, | Teva Pharmaceuticals

Tal holds a PhD in Biochemistry from the Graduate Center of the City University of New York. Tal’s PhD research focused on utilizing genomic tools to identify and isolate active constituents from Japanese herbal medicine. Upon completing his thesis, Tal joined Teva at 2009 as a principal scientist working in the innovative analytical development group. Tal’s focus was to develop new tools to characterize different physiochemical properties of Copaxone, as part of an ongoing effort to distinguish Copaxone from generics. Tal also served as an analytical team leader in the specialty CMC department. In addition, Tal led a numerous CMC projects spanning from pre-clinical phase to post marketing, recently leading the CMC efforts for Azilect Japan. In the past year, Tal moved to the Generic R&D division from which, he is leading all CMC and analytical activities associated with Copaxone and Azilect. Speakers - 2019

Yael Marantz, PhD VP Nonclinical development, and head of ABIC site in IL | Teva Pharmaceuticals

Yael received her bachelor's degree in chemistry, her Master's degree in biochemistry, focusing on signal transduction of the GnRH receptor, and a PhD in biophysics, on proton transfer mechanism in Cytochromes, all from Tel Aviv university. Yael was a founding scientist in a biotech company called EPIX pharmaceutical - a pharmaceutical company based in Lexington MA and Ramat-Gan IL, developing drugs for CNS and inflammation (GPCR's).Yael was involved in the discovery of all the company pipeline (four of them reached clinical trials) and served as a VP computational drug development, head of the IL site (30 employees) a member in the executive team, as well as a member of joint research committees with GSK, Amgen and the CFTR foundation. Yael joined Teva 9 years ago as a project champion for four biosimilar. As part of her role, she developed early clinical plans, set the overall work plan and interacted with many functions in the company including commercial, IP, nonclinical, clinical etc. Later on Yael assumed for a short period the role of a project champion for both Azilect and Copaxone focusing on LCM activities, new clinical trials, NDA preparation for new Azilect formulation (not submitted) and preparation for the approval of the 40mg Copaxone. Soon after the Cephalon integration, Yael assumed the role of head of nonclinical. Through these years this role has evolved and she is now responsible for a global group of 130 people in the fields of Tox, DMPK, pharmacology as well as bioanalytical/immunogenicity and biomarkers assays group and supports the specialty, generic and TGO organization in various aspects. Through her years in Teva, Yael participated in many company initiatives such as Spring, STEP and was part of the team working on our company leadership frame work. In the last 6 years she is also the head of Abic site.

Yuval Cabilly, PhD | Founder and Managing Partner, Israel Biotech Fund

Dr. Cabilly is one of the three founders and a Managing Partner of Israel Biotech Fund. Israel Biotech Fund is a fundamental biotech VC focusing on Israeli and Israeli related pharmaceutical companies with exceptional technologies or product opportunities based on strong scientific rationale and commercial potential. The Fund’s key differentiator from other funds is the active involvement of its Venture Advisory team, comprised of more than 25 industry leaders and professionals. To date, Israel Biotech Fund has invested in six pharmaceutical companies in various development stages, including one which was incorporated by the Fund and one which went public in October 2018. By providing capital, executive talent, strategic, operational, and business development resources, the Fund enables its portfolio companies to design and execute clinical development programs. Dr. Cabilly serves on the Board of Directors of TPCera Ltd. and is an Observer of the Board of Directors of Pharma Two B Ltd. Dr. Cabilly is also co-founder and Board Member of 8400 – The Health Network. Prior to the formation of the Fund, Dr. Cabilly managed the investment portfolio of the Cabilly family, which focuses primarily on healthcare start-ups in Israel and elsewhere. Dr. Cabilly was responsible for identifying, funding and engaging in business development activities for its 20+ companies, including seven Israeli Pharma start-ups in pre-clinical, Phase I and Phase II clinical stages. Dr. Cabilly received his Ph.D. in molecular cell biology from Tel Aviv University, where he focused his research on a neurodegenerative disease, and several of his articles have been published in well-known scientific journals. Dr. Cabilly is based in Israel and devotes his full time to managing the Fund. Speakers - 2019

Mr. Yoav Grinstein | COO, Our Clinical Trial

A technological and operation leader with more than 16 years of experience in Project Management, Medical Device and Pharmaceutical (Teva) companies dreaming and building new technology solutions in clinical data management and clinical operations, leading complex projects in regulated environments, accelerating innovation, implementing noble work processes while developing high-performance teams.

Mr. Zohar Gendler | Managing Partner and CEO, NGT3

Managing Partner & CEO of NGT3 which is an early-stage investor structured as a venture capital fund and a holder the Israeli government franchise to operate technological incubator and invest in life-science technologies. NGT portfolio currently includes a diverse portfolio of 16 companies in the fields of medical devices, biotech and pharma. Former CEO and director of Beta-O2 Technologies for a period of 8 years (a biomedical company which developed proprietary implantable bio-artificial pancreas), brought the company to one of the world leaders positioning in the area. Served as CEO of the Technion Entrepreneurial Incubator for a period of 11 years. Led the establishment and investment in more than 50 companies, such as Prolor Biotech (sold to Opko, NYSE: OPK, for $480M), (sold to Medtronics, for $1.6B), (NASDAQ: RWLK, www.rewalk.com), Corindus (NASDAQ: CVRS, www.corindus.com), Regentis (www.regentis.co.il), Medic Vision (http://www.medicvision.com/usa/home), and many others. Gained a wide range of experience in identifying new technologies and in establishing, directing, and creating value for technology-based start-up companies. Served as a member of the Technion’s Patent Committee. (1998 – 2006). Earned his M.Sc. in material engineering, a B.Sc. in physics, and a certificate in business management, all from the Technion, Israel Institute of Technology. Organizing Committee

Liron Even-Faitelson, PhD Tal Yoetz-Kopelman, PhD Liron has a PhD in biochemistry and cell biology Dr. Tal Yoetz-Kopelman is currently a manager from the Hebrew University of Jerusalem. at the Academic Affairs and Networks department at teva’s innovative R&D. Tal has a Her PhD studies were followed by postdoctoral PhD in Biotechnology and Physical Electronics training in genetic engineering in the Plant from Tel-Aviv University and an MSc and BSc in Sciences department at the Weizmann Institute Biotechnology Engineering from Ben-Gurion and then, a second postdoc in the Genetics University (both Magna cum Laude). and Genome Biology department at Sickkids Hospital, Toronto, Canada. During her last year During her PhD studies Tal chaired the as a postdoc, she established ScienceAbroad’s Electrochemical Society Student Chapter at Tel (then BioAbroad) center in Toronto. Aviv University. Tal joined teva at 2016 as a senior researcher in the formulation department of the innovative R&D . Nowadays, Liron is a professional content consultant and special projects manager at ScienceAbroad, a Masters student in the Integrated Design program at Holon Institute of Technology and an advisor to European Research Networks at the chief scientist office in the Ministry of Health. Together with a husband, three kids, two cats and two chinchillas she keeps busy.

Great minds think ISRAEL

תודתנו לנותני החסות

תודתנו לשותפים שלנו

Contact Information:

Liron Even-Faitelson Tal Yoetz Monika Lev Cohen Anat Weiss [email protected] [email protected] [email protected] [email protected] 053-2800793 054-8886347 052-3847949 050-5617246